Workflow
股价迎考!*ST长药涉嫌财务造假遭立案,存强制退市风险

Core Viewpoint - *ST Changyao has been placed under delisting risk warning due to operational pressures and has now received further negative news regarding a formal investigation by the China Securities Regulatory Commission (CSRC) for suspected false financial reporting [1][3]. Financial Performance - For the years 2022 to 2024, *ST Changyao reported revenues of approximately 1.615 billion, 1.198 billion, and 112 million respectively, with net profits of -23 million, -606 million, and -628 million [3]. - In the first three quarters of this year, the company achieved a revenue of 105 million, a year-on-year increase of 4.4%, while the net profit was -210 million, a year-on-year decrease of 15.89% [4]. Regulatory and Legal Issues - The CSRC has issued a notice of investigation due to suspected false recording of financial data, which could lead to significant legal repercussions for the company [1][3]. - If the CSRC confirms violations that meet the criteria for mandatory delisting under the Shenzhen Stock Exchange rules, the company's stock may face forced delisting [3]. Asset and Debt Situation - As of the end of the third quarter, *ST Changyao's net assets were reported at -643 million, worsening from -433 million at the end of 2024 [3]. - The company is currently undergoing a pre-restructuring phase, with a court decision extending this period until January 20, 2026 [4]. Bankruptcy and Restructuring Risks - The company faces significant risks related to its restructuring process, including the possibility of failure to pass restructuring plans or court approval, which could lead to bankruptcy [5]. - There are currently 140 ongoing lawsuits and arbitration cases involving the company, with a total amount in dispute of 1.878 billion, representing 434% of the company's latest audited net assets [5].